Radiation therapy for prostate cancer can be delivered from outside the body (external beam radiation therapy, or EBRT) or from within the prostate itself. The internal approach is called brachytherapy, from the Greek word for "short distance." It works by placing radioactive sources directly inside or adjacent to the tumor, delivering intense local radiation while sparing surrounding structures.
Two main forms of brachytherapy are used for prostate cancer. Low dose-rate (LDR) brachytherapy uses permanent radioactive seeds implanted into the prostate that slowly release radiation over weeks to months. High dose-rate (HDR) brachytherapy, by contrast, involves temporarily placing hollow plastic catheters through the prostate, then using a robotic device to advance a highly radioactive source -- typically Iridium-192 or Cobalt-60 -- through each catheter for a calculated time before withdrawing it. The entire treatment is completed in one or a few sessions.
HDR brachytherapy offers several advantages over LDR. The dose distribution can be optimized in real time by controlling how long the source dwells at each position, the catheters are removed after treatment so there is no permanent implant, and the technique is compatible with very large doses per fraction -- a property that turns out to be particularly well suited to the biology of prostate cancer.
The sensitivity of tissue to the size of each radiation dose fraction is described by the alpha/beta ratio, a parameter derived from the linear-quadratic model of cell killing. Most tumors have high alpha/beta ratios (around 10 Gy), meaning they are relatively insensitive to fraction size. Normal tissues tend to have lower ratios around 3 Gy, meaning they respond more strongly to larger fractions.
Prostate cancer is biologically unusual: multiple lines of evidence suggest its alpha/beta ratio is very low -- potentially 1.5 Gy or even lower than 1.0 Gy -- possibly lower than the surrounding normal tissues of the rectum and bladder. If true, this means prostate cancer cells are more sensitive to large radiation doses per fraction than the normal tissues around them, inverting the usual therapeutic calculus.
This unique biology provides a strong rationale for hypofractionation -- delivering fewer but larger doses of radiation. HDR brachytherapy is the ultimate hypofractionated approach, capable of delivering very high doses per fraction in one to three treatments. If the alpha/beta ratio for prostate cancer is truly below 1.5 Gy, HDR brachytherapy achieves a therapeutic advantage not just from its physical precision but from a fundamental biological property of the tumor itself.
HDR brachytherapy begins with implanting hollow catheters through the perineum (the region between the legs) into the prostate under transrectal ultrasound (TRUS) guidance while the patient is under anesthesia. A standard implant uses approximately 16 catheters -- typically 12 around the prostate periphery and 4 in the central region -- though this varies by gland size and shape. A template grid ensures accurate placement.
Once catheters are placed, a 3D treatment plan is generated that specifies how long the radioactive source pauses (dwells) at each position within each catheter. Modern inverse planning algorithms optimize these dwell times automatically to meet dosimetric goals: delivering at least 95% of the prescription dose to the prostate target volume while keeping dose to the rectum, bladder, and urethra below established safety thresholds.
A key practical advantage of HDR over EBRT is that the plan can be adapted to the patient's anatomy on the day of treatment. Because catheters are placed and the plan generated on the same day, there is no concern about organ motion between the planning scan and treatment delivery -- a persistent challenge for EBRT. TRUS-based real-time planning is the preferred approach because the patient remains in position throughout planning and delivery, eliminating setup uncertainty entirely.
The most extensively studied application of HDR brachytherapy is as a boost combined with external beam radiation therapy (EBRT). In this approach, EBRT treats the prostate and sometimes the pelvic lymph nodes to a moderate dose, and one to two HDR fractions then deliver an intensified dose to the prostate itself. The combination exploits the precision of brachytherapy to safely escalate the total biologically effective dose beyond what EBRT alone can achieve.
Three randomized controlled trials have directly compared HDR boost plus EBRT to EBRT alone. All three demonstrated significant reductions in biochemical recurrence -- the return of a rising PSA after treatment -- with 31% to 50% relative reductions in recurrence risk in the HDR-boosted arms. These results established HDR boost as a superior option to dose-escalated EBRT alone for intermediate and high-risk prostate cancer.
Outcomes data from large patient series are highly favorable. Across more than 6,000 patients treated with HDR boost combinations, 5-year disease-free survival rates are approximately 95% for low-risk, 91% for intermediate-risk, and 82% for high-risk disease. A commonly used current regimen delivers a single HDR fraction of 15 Gy combined with 37.5 Gy in 15 EBRT fractions, completed in 3 weeks -- a highly abbreviated schedule compared to traditional 8-week EBRT courses.
Androgen deprivation therapy (ADT) is typically combined with HDR boost for intermediate and high-risk patients. The combination of hormonal therapy, dose-escalated brachytherapy, and EBRT represents the most intensive local treatment approach available and is associated with the best disease control rates in men with aggressive localized prostate cancer.
HDR monotherapy -- using brachytherapy as the sole radiation treatment without any EBRT -- has emerged as an option for low- and intermediate-risk prostate cancer. The appeal is treating the entire course of radiation in just one to three visits, a radical reduction from the 8 to 9 weeks required for conventional EBRT or the permanent implant required for LDR brachytherapy.
The most established monotherapy regimens use two or three fractions. Schedules such as 27 Gy in 2 fractions or 34.5 Gy in 3 fractions have been used in large cohort studies with favorable 5-year outcomes. These multi-fraction approaches allow some normal tissue recovery between treatments and have a well-documented safety profile. At 5 years, biochemical control rates of approximately 90% or better have been reported for appropriately selected patients.
Single-fraction HDR monotherapy, typically 19-20 Gy in one treatment, is the most extreme hypofractionated approach. Early phase I/II studies showed promising PSA response rates, but conflicting data emerged from larger series. One trial reported a 5-year biochemical disease-free survival of only 68.4% with 19 Gy -- substantially lower than multi-fraction approaches -- raising questions about whether single-fraction is truly sufficient. The optimal single-fraction dose remains an active research question.
Patient selection is critical for monotherapy. Men with very large prostates may have difficulty achieving adequate target coverage and adequate urethral sparing simultaneously. Most centers restrict monotherapy to patients with prostate volumes below 60-80 cc. Baseline urinary symptoms are also evaluated, since brachytherapy can cause transient urinary irritation, making pre-existing urethral obstruction a relative contraindication.
Approximately 20-40% of men treated with radiation for prostate cancer will experience biochemical recurrence -- a rising PSA level -- within 10 years. For many years, re-irradiation of the prostate was considered too dangerous because cumulative radiation doses to the bladder, rectum, and urethra were thought to exceed safe limits. HDR brachytherapy has revived interest in local salvage therapy because of its exceptional ability to spare normal tissues.
Salvage HDR brachytherapy targets the prostate or a specific region of recurrence identified on multi-parametric MRI (mpMRI) or PSMA PET scanning. Focal salvage -- treating only the visible recurrence rather than the whole gland -- is increasingly used because it reduces toxicity while still treating the clinically relevant disease. Studies report 5-year disease-free survival rates of approximately 45-69% in carefully selected patients, which is remarkable given that these patients had already failed prior radiation.
The toxicity profile of salvage HDR is acceptable when patients are carefully selected and techniques are optimized. Grade 3 or higher urinary toxicity occurs in approximately 10-15% of patients, and grade 3 rectal toxicity in fewer than 5%, in published series. A minimum interval of 2-3 years between initial radiation and salvage HDR, along with confirmation that recurrence is truly local rather than metastatic, is essential for appropriate patient selection.
The most common acute side effects of HDR brachytherapy are urinary symptoms -- increased frequency, urgency, and burning -- caused by radiation to the urethra passing through the center of the prostate. These symptoms peak in the first 2-4 weeks after treatment and resolve in most patients within 3-6 months. Rectal symptoms such as urgency and loose stools are less common and typically mild, reflecting the technique's ability to keep rectal doses well below threshold levels.
Late toxicity rates are favorably low. Grade 2 or higher late urinary toxicity occurs in approximately 15-20% of patients and grade 2 or higher rectal toxicity in approximately 5% -- rates that compare favorably to or better than intensity-modulated radiation therapy (IMRT) in matched comparisons. Urethral stricture, the most serious late urinary complication, occurs in 1-5% of patients and can usually be managed endoscopically.
Erectile function is preserved in approximately 40-60% of patients who were potent before HDR brachytherapy, which is comparable to outcomes after nerve-sparing radical prostatectomy and better than what is typically achieved with EBRT plus androgen deprivation therapy. Quality-of-life studies consistently show that bowel function is better preserved after HDR than after IMRT, and urinary function largely recovers to baseline within 6-12 months in most patients.
HDR brachytherapy is moving toward further consolidation of treatment, with ongoing trials exploring the optimal single-fraction dose for monotherapy. Doses of 19-20 Gy appear at the lower boundary of efficacy, and current trials are testing 24 Gy in a single fraction to determine whether higher single doses can match multi-fraction outcomes while maintaining safety. The extreme convenience of a single-treatment course makes this question clinically important.
Integration with PSMA PET-CT and advanced mpMRI is reshaping patient selection and target definition. These imaging technologies can identify intra-prostatic tumor foci with much greater confidence than conventional imaging, enabling more precise focal boosting. The ability to treat only the region of visible dominant tumor while minimizing dose to the rest of the gland may reduce toxicity while maintaining excellent control of the dominant cancer clone.
Overall, HDR brachytherapy represents one of the most sophisticated radiation delivery techniques available for prostate cancer, combining exceptional dosimetric precision with biological advantages derived from the unusual radiobiology of prostate tumors. It is appropriate for low, intermediate, and high-risk localized disease either as monotherapy or as a boost with EBRT, and for selected patients with locally recurrent disease. The key to successful outcomes lies in experienced implant technique, rigorous dosimetric planning, and careful patient selection based on clinical, pathological, and imaging parameters.